-
-
-
-
-
-
-
Veru, Inc. (VERU) Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at ESMO
-
-
-
-
-
-
-
Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology
-
-
-
-
-
-
-
Veru to Present at the Jefferies Virtual Healthcare Conference
-
-
-
-
-
-
-
Veru, Inc. (VERU) Submits New Drug Application for Proprietary TADFIN for BPH
-
-
15,414 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

